[Re-administration of drotrecogin alfa activated in a patient with episodes of severe sepsis].
Verdú
M T
MT
Sánchez
Ortega J L
OJ
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005440:Fluid Therapy; D005756:Gastritis / Q000209:etiology; D006801:Humans; D007416:Intestinal Perforation / Q000150:complications / Q000601:surgery; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000209:etiology; D010538:Peritonitis / Q000188:drug therapy / Q000209:etiology; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D019106:Postoperative Hemorrhage / Q000139:chemically induced*; D011486:Protein C / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000209:etiology / Q000628:therapy; D012772:Shock, Septic / Q000150:complications / Q000188:drug therapy*; D013529:Surgical Wound Dehiscence; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; D014662:Vasoconstrictor Agents; C421124:drotrecogin alfa activated